Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trialParesh Dandona, Bertrand Cariou, Steven C. Griffen et al.|The Lancet Diabetes & Endocrinology|2017Cited by 295
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY AnalysisPeter Rossing, Duncan J. Topliss, Stefan D. Anker et al.|Diabetes Care|2022Cited by 207